arrow
A

Ahwan Pandey

Peter MacCallum Cancer Centre
H指数:23
被引数:2,296

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma

BRCA缺陷性输卵管卵巢高级别浆液性癌的生存临床病理及分子预测因子

2026-04-010
OAAI
Clinical and molecular predictors of outcome in patients with tubo-ovarian high-grade serous carcinoma and exceptional survival

输卵管卵巢高级别浆液性癌患者结局的临床与分子预测因子及特殊生存情况

2024-09-010
PRE
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

同时RB1丢失和BRCA缺乏可预测输卵管卵巢高级别浆液性癌的免疫反应增强和长期生存

2024-06-050
OAAI
Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities (vol 8, 68, 2024)

富集HGSOC肿瘤上皮的蛋白质基因组分析确定预后特征和治疗弱点 (vol 8,68,2024)

2024-05-060
OAAI
Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities

富集HGSOC肿瘤上皮的蛋白质基因组分析确定预后特征和治疗脆弱性

2024-03-132
OAAI
Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC Implications for surgical and clinical outcomes
2023-06-0112
OAAI
FAM193A is a positive regulator of p53 activity
2023-03-012
OAAI
Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer

同源重组缺陷型终末期高级别浆液性卵巢癌的多组学分析

2023-02-2728
PRE
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer
2022-12-0135
OA
Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome
2019-11-0181
OAAI